NTGN - Neon's Data In Cancer Study Points To Personalized Treatment Advancement In Immunotherapy Space
Neon Therapeutics (NTGN) announced that it had achieved positive results using a personalized cancer treatment known as NEO-PV-01 in a couple types of cancer. Specifically, combining the biotech's vaccine treatment together with OPDIVO to achieve improved clinical outcomes. The combination was able to achieve prolonged and improved median progression-free survival (mPFS) rates in a few types of cancer. With this data on hand, I believe the biotech is equipped to move forward with additional studies. If NEO-PV-01 is able to prolong mPFS rates of checkpoint inhibitors, then it would truly be a highly ideal outcome.